AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System
11. August 2022 16:05 ET
|
AVITA Medical
AVITA Medical plans to submit PMA supplement for this new indication to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc....
AVITA Medical to Announce Second Quarter 2022 Financial Results
25. Juli 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif., and MELBOURNE, Australia, July 25, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Reports First Quarter 2022 Financial Results
12. Mai 2022 16:14 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and...
RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
09. Mai 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and...
AVITA Medical to Announce First Quarter 2022 Financial Results
28. April 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, April 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors
21. April 2022 09:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, April 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and...
RECELL® System Data to be Presented at the American Burn Association Annual Meeting
04. April 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
23. März 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction
21. März 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
02. März 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...